Cyclacel plc postponed its proposed dual listing on Nasdaq and the London Stock Exchange, citing market conditions, as Evolutec Group plc succeeded in getting its modest initial public offering away on London’s Alternative Investment Market, raising £5.1 million (US$9.4 million) net of the £7.5 million net it had hoped for.
